The Mark Foundation for Cancer Research
@themarkfdn.bsky.social
Partnering with scientists to accelerate transformation in cancer research.
Pinned
The Mark Foundation for Cancer Research | Our Impact
Learn how The Mark Foundation for Cancer Research is accelerating progress in the fight against cancer.
vimeo.com
Hello, Bluesky! Follow along for updates on our work and the researchers we support. New to The Mark Foundation? Check out this video to learn how we accelerate progress in the fight against cancer.
#CancerResearch #ResearchFunding
vimeo.com/1013135446
#CancerResearch #ResearchFunding
vimeo.com/1013135446
We're back from the @theaacr.bsky.social Special Conference on Early Onset Cancers! A major highlight was the update from Mark Foundation-Waxman Foundation grantee Ashani Weeraratna on her research into how the aging tumor immune microenvironment influences tumor progression. #AACRearlyonset25
December 15, 2025 at 9:23 PM
We're back from the @theaacr.bsky.social Special Conference on Early Onset Cancers! A major highlight was the update from Mark Foundation-Waxman Foundation grantee Ashani Weeraratna on her research into how the aging tumor immune microenvironment influences tumor progression. #AACRearlyonset25
What happens when the scientist becomes the subject?
Emerging Leader Award winner Ansuman Satpathy & collaborator Caleb Laureau are challenging conventional wisdom in genetics using findings from Satpathy’s own DNA.
themarkfoundation.org/blog/the-sci...
Emerging Leader Award winner Ansuman Satpathy & collaborator Caleb Laureau are challenging conventional wisdom in genetics using findings from Satpathy’s own DNA.
themarkfoundation.org/blog/the-sci...
The Scientist Becomes the Subject: Ansuman Satpathy, MD, PhD | The Mark Foundation for Cancer Research
If you took a close look at your own DNA, what might you find? For 2025 Mark Foundation Emerging Leader Award winner Ansuman Satpathy, MD, PhD, the answer turned out to be a groundbreaking discovery.
themarkfoundation.org
December 10, 2025 at 7:36 PM
What happens when the scientist becomes the subject?
Emerging Leader Award winner Ansuman Satpathy & collaborator Caleb Laureau are challenging conventional wisdom in genetics using findings from Satpathy’s own DNA.
themarkfoundation.org/blog/the-sci...
Emerging Leader Award winner Ansuman Satpathy & collaborator Caleb Laureau are challenging conventional wisdom in genetics using findings from Satpathy’s own DNA.
themarkfoundation.org/blog/the-sci...
Reposted by The Mark Foundation for Cancer Research
📢 New Impact Report from SPECIFICANCER, the team unravelling one of cancer biology’s hardest puzzles: tissue specificity.
A huge thank you to the team and thanks to our co-funders, @themarkfdn.bsky.social and @cancerresearchuk.org for supporting global science.
🔗 lnkd.in/dQC-iHmK
A huge thank you to the team and thanks to our co-funders, @themarkfdn.bsky.social and @cancerresearchuk.org for supporting global science.
🔗 lnkd.in/dQC-iHmK
December 8, 2025 at 3:38 PM
📢 New Impact Report from SPECIFICANCER, the team unravelling one of cancer biology’s hardest puzzles: tissue specificity.
A huge thank you to the team and thanks to our co-funders, @themarkfdn.bsky.social and @cancerresearchuk.org for supporting global science.
🔗 lnkd.in/dQC-iHmK
A huge thank you to the team and thanks to our co-funders, @themarkfdn.bsky.social and @cancerresearchuk.org for supporting global science.
🔗 lnkd.in/dQC-iHmK
The Mark Foundation scientific community will be well represented at #ASH25! Heading to Orlando? Don't miss these presentations, moderated sessions, and posters from our grantees.
themarkfoundation.org/blog/mark-fo...
themarkfoundation.org/blog/mark-fo...
Mark Foundation Scientific Community at ASH 2025: Driving Progress on Hematological Malignancies | The Mark Foundation for Cancer Research
The American Society of Hematology (ASH) Annual Meeting is the biggest meeting on the global hematology community’s calendar — and we’re proud to see a significant representation from the Mark…
themarkfoundation.org
December 4, 2025 at 9:16 PM
The Mark Foundation scientific community will be well represented at #ASH25! Heading to Orlando? Don't miss these presentations, moderated sessions, and posters from our grantees.
themarkfoundation.org/blog/mark-fo...
themarkfoundation.org/blog/mark-fo...
From bench to bedside! In a Phase 1 trial, a vaccine targeting a neoantigen in fibrolamellar hepatocellular carcinoma (FLC), a rare liver cancer primarily affecting younger people, showed significant clinical benefit when combined with immune checkpoint inhibitors. www.nature.com/articles/s41...
December 4, 2025 at 9:07 PM
From bench to bedside! In a Phase 1 trial, a vaccine targeting a neoantigen in fibrolamellar hepatocellular carcinoma (FLC), a rare liver cancer primarily affecting younger people, showed significant clinical benefit when combined with immune checkpoint inhibitors. www.nature.com/articles/s41...
Every day counts in the fight against cancer—and we can’t afford to let reduced federal funding slow progress. Your support this #GivingTuesday helps The Mark Foundation fund ambitious science and bring breakthroughs to the patients who need them. themarkfoundation.org/donate/
December 2, 2025 at 3:00 PM
Every day counts in the fight against cancer—and we can’t afford to let reduced federal funding slow progress. Your support this #GivingTuesday helps The Mark Foundation fund ambitious science and bring breakthroughs to the patients who need them. themarkfoundation.org/donate/
Reposted by The Mark Foundation for Cancer Research
Read the newly published impact report from the SPECIFICANCER team that reshaped our understanding of tissue specificity.
Thanks to our co-funders, @themarkfdn.bsky.social, for supporting the #CancerGrandChallenges team and global science.
🔗 lnkd.in/eDrQ9guu
Thanks to our co-funders, @themarkfdn.bsky.social, for supporting the #CancerGrandChallenges team and global science.
🔗 lnkd.in/eDrQ9guu
December 1, 2025 at 4:48 PM
Read the newly published impact report from the SPECIFICANCER team that reshaped our understanding of tissue specificity.
Thanks to our co-funders, @themarkfdn.bsky.social, for supporting the #CancerGrandChallenges team and global science.
🔗 lnkd.in/eDrQ9guu
Thanks to our co-funders, @themarkfdn.bsky.social, for supporting the #CancerGrandChallenges team and global science.
🔗 lnkd.in/eDrQ9guu
Reposted by The Mark Foundation for Cancer Research
What a wonderful few days we've had together in Bergamo at The Rise of Early-Onset Cancers 🎉
Thank you to everyone who attended, our co-organisers @themarkfdn.bsky.social and to the Scientific Programme Committee for all the dedication they put into the great science showcased in the conference!
Thank you to everyone who attended, our co-organisers @themarkfdn.bsky.social and to the Scientific Programme Committee for all the dedication they put into the great science showcased in the conference!
November 14, 2025 at 12:32 PM
What a wonderful few days we've had together in Bergamo at The Rise of Early-Onset Cancers 🎉
Thank you to everyone who attended, our co-organisers @themarkfdn.bsky.social and to the Scientific Programme Committee for all the dedication they put into the great science showcased in the conference!
Thank you to everyone who attended, our co-organisers @themarkfdn.bsky.social and to the Scientific Programme Committee for all the dedication they put into the great science showcased in the conference!
Reposted by The Mark Foundation for Cancer Research
Members of NexTGen (co-funded by @themarkfdn.bsky.social), Nikolaos Sgourakis & John Maris, contributed to a new Nature paper from David Baker’s lab showing AI-designed antibodies with atomic-level precision
A potential game-changer 👉
nature.com/articles/s41586-025-09721-5
A potential game-changer 👉
nature.com/articles/s41586-025-09721-5
Atomically accurate de novo design of antibodies with RFdiffusion - Nature
The combination of computational design, laboratory-based screening and biophysical validation enables the de novo generation of variable heavy-chain antibody fragments and antibodies that precis...
nature.com
November 11, 2025 at 12:39 PM
Members of NexTGen (co-funded by @themarkfdn.bsky.social), Nikolaos Sgourakis & John Maris, contributed to a new Nature paper from David Baker’s lab showing AI-designed antibodies with atomic-level precision
A potential game-changer 👉
nature.com/articles/s41586-025-09721-5
A potential game-changer 👉
nature.com/articles/s41586-025-09721-5
It's been a productive 3 days in Bergamo, Italy, at the @helloeacr.bsky.social - Mark Foundation Joint Conference: The Rise of Early-Onset Cancers! Participants have shared new insights into the rise in cancer among young patients & identified paths forward for prevention, detection, & treatment.
November 13, 2025 at 12:26 PM
It's been a productive 3 days in Bergamo, Italy, at the @helloeacr.bsky.social - Mark Foundation Joint Conference: The Rise of Early-Onset Cancers! Participants have shared new insights into the rise in cancer among young patients & identified paths forward for prevention, detection, & treatment.
Reposted by The Mark Foundation for Cancer Research
Prof. Sir Mike Stratton delivers his keynote lecture at the close of The Rise of Early-Onset Cancers in Bergamo.
We're very grateful for the partnership of @themarkfdn.bsky.social in this groundbreaking joint conference, which has explored a critical and underexplored frontier in cancer biology.
We're very grateful for the partnership of @themarkfdn.bsky.social in this groundbreaking joint conference, which has explored a critical and underexplored frontier in cancer biology.
November 13, 2025 at 10:41 AM
Prof. Sir Mike Stratton delivers his keynote lecture at the close of The Rise of Early-Onset Cancers in Bergamo.
We're very grateful for the partnership of @themarkfdn.bsky.social in this groundbreaking joint conference, which has explored a critical and underexplored frontier in cancer biology.
We're very grateful for the partnership of @themarkfdn.bsky.social in this groundbreaking joint conference, which has explored a critical and underexplored frontier in cancer biology.
Reposted by The Mark Foundation for Cancer Research
We're so grateful to our partners at the @themarkfdn.bsky.social for supporting the NexTGen team and helping to make their research possible.
Thank you to all our #CancerGrandChallenge partners who make progress possible 👏
Thank you to all our #CancerGrandChallenge partners who make progress possible 👏
Team NexTGen, featured in @washingtonpost.com discussing their CAR T-cell immunotherapy trial.
Thank you to @themarkfdn.bsky.social for supporting global science - working together to tackle one of the toughest challenges in cancer.
👉 If you have access - www.washingtonpost.com/science/2025...
Thank you to @themarkfdn.bsky.social for supporting global science - working together to tackle one of the toughest challenges in cancer.
👉 If you have access - www.washingtonpost.com/science/2025...
November 4, 2025 at 9:32 AM
We're so grateful to our partners at the @themarkfdn.bsky.social for supporting the NexTGen team and helping to make their research possible.
Thank you to all our #CancerGrandChallenge partners who make progress possible 👏
Thank you to all our #CancerGrandChallenge partners who make progress possible 👏
The @theaacr.bsky.social–Mark Foundation Chemistry in Cancer Research Grants are now accepting Letters of Intent!
We’re seeking bold, innovative approaches in chemistry and chemical biology to tackle the biggest challenges in cancer.
Learn more and apply: www.aacr.org/grants/aacr-...
We’re seeking bold, innovative approaches in chemistry and chemical biology to tackle the biggest challenges in cancer.
Learn more and apply: www.aacr.org/grants/aacr-...
November 5, 2025 at 1:13 PM
The @theaacr.bsky.social–Mark Foundation Chemistry in Cancer Research Grants are now accepting Letters of Intent!
We’re seeking bold, innovative approaches in chemistry and chemical biology to tackle the biggest challenges in cancer.
Learn more and apply: www.aacr.org/grants/aacr-...
We’re seeking bold, innovative approaches in chemistry and chemical biology to tackle the biggest challenges in cancer.
Learn more and apply: www.aacr.org/grants/aacr-...
🎉Three members of The Mark Foundation’s community —
@charlesswanton.bsky.social, Michel Sadelin, and Victor Velculescu — were elected to @nam.edu yesterday!🎉
Learn more about their remarkable achievements:
themarkfoundation.org/blog/three-m...
@charlesswanton.bsky.social, Michel Sadelin, and Victor Velculescu — were elected to @nam.edu yesterday!🎉
Learn more about their remarkable achievements:
themarkfoundation.org/blog/three-m...
Three Mark Foundation Community Members Elected to the National Academy of Medicine | The Mark Foundation for Cancer Research
Yesterday, the National Academy of Medicine announced the election of 90 new regular members and 10 international members in recognition of their outstanding professional achievement and commitment to...
themarkfoundation.org
October 21, 2025 at 9:29 PM
🎉Three members of The Mark Foundation’s community —
@charlesswanton.bsky.social, Michel Sadelin, and Victor Velculescu — were elected to @nam.edu yesterday!🎉
Learn more about their remarkable achievements:
themarkfoundation.org/blog/three-m...
@charlesswanton.bsky.social, Michel Sadelin, and Victor Velculescu — were elected to @nam.edu yesterday!🎉
Learn more about their remarkable achievements:
themarkfoundation.org/blog/three-m...
New in @nature.com: ASPIRE awardee @loisher.bsky.social of @petermaccc.bsky.social shows that pregnancy & breastfeeding cause long-lasting immunological changes that significantly reduce breast cancer risk, especially for triple-negative breast cancer. themarkfoundation.org/blog/aspire-...
ASPIRE Awardee Reveals How Pregnancy and Breastfeeding Protect Against Breast Cancer | The Mark Foundation for Cancer Research
Since the 1980s, researchers have known that pregnancy and breastfeeding reduce women’s risk of later developing breast cancer — but the reason why has remained a mystery…
themarkfoundation.org
October 20, 2025 at 4:26 PM
New in @nature.com: ASPIRE awardee @loisher.bsky.social of @petermaccc.bsky.social shows that pregnancy & breastfeeding cause long-lasting immunological changes that significantly reduce breast cancer risk, especially for triple-negative breast cancer. themarkfoundation.org/blog/aspire-...
📢Calling all Mark Foundation grantees (past and current) & advisors! 📢
Check your inboxes - you should have received your invite to our 2026 Scientific Symposium. Haven't seen it? Send us a note at events@themarkfoundation.org.
Check your inboxes - you should have received your invite to our 2026 Scientific Symposium. Haven't seen it? Send us a note at events@themarkfoundation.org.
October 20, 2025 at 3:23 PM
📢Calling all Mark Foundation grantees (past and current) & advisors! 📢
Check your inboxes - you should have received your invite to our 2026 Scientific Symposium. Haven't seen it? Send us a note at events@themarkfoundation.org.
Check your inboxes - you should have received your invite to our 2026 Scientific Symposium. Haven't seen it? Send us a note at events@themarkfoundation.org.
Huge congratulations to @rosslevinemd.bsky.social, who has been named @mskcancercenter.bsky.social's new Chief Scientific Officer! We’re deeply grateful to have his expertise on our Board of Directors and as Chair of our Scientific Advisory Committee.
www.mskcc.org/news-release...
www.mskcc.org/news-release...
October 16, 2025 at 8:26 PM
Huge congratulations to @rosslevinemd.bsky.social, who has been named @mskcancercenter.bsky.social's new Chief Scientific Officer! We’re deeply grateful to have his expertise on our Board of Directors and as Chair of our Scientific Advisory Committee.
www.mskcc.org/news-release...
www.mskcc.org/news-release...
Why does immunotherapy rarely lead to a complete cure?|
In @cellpress.bsky.social, ASPIRE awardee Charles Swanton tracks the lineages of tumor subclones & suggests that subclonal evolution allows some cells to evade immune attack. #CancerResearch #Immunology
www.cell.com/cancer-cell/...
In @cellpress.bsky.social, ASPIRE awardee Charles Swanton tracks the lineages of tumor subclones & suggests that subclonal evolution allows some cells to evade immune attack. #CancerResearch #Immunology
www.cell.com/cancer-cell/...
Subclonal immune evasion in non-small cell lung cancer
Dijkstra et al. investigate whether individual cancer subclones differ in their immune
evasion capacity. They establish organoids representing distinct subclones from multi-region
lung cancer biopsies...
www.cell.com
October 15, 2025 at 2:10 PM
Why does immunotherapy rarely lead to a complete cure?|
In @cellpress.bsky.social, ASPIRE awardee Charles Swanton tracks the lineages of tumor subclones & suggests that subclonal evolution allows some cells to evade immune attack. #CancerResearch #Immunology
www.cell.com/cancer-cell/...
In @cellpress.bsky.social, ASPIRE awardee Charles Swanton tracks the lineages of tumor subclones & suggests that subclonal evolution allows some cells to evade immune attack. #CancerResearch #Immunology
www.cell.com/cancer-cell/...
Reposted by The Mark Foundation for Cancer Research
This collaborative project would not have be possible w/o JP and our wonderful colleagues (many not on social), and support from @damonrunyon.org and @themarkfdn.bsky.social!
October 10, 2025 at 4:13 PM
This collaborative project would not have be possible w/o JP and our wonderful colleagues (many not on social), and support from @damonrunyon.org and @themarkfdn.bsky.social!
The Emerging Leader Award program “lets people follow where the science goes,” says 2019 winner Andrew Lane. That flexibility has allowed him to bring discoveries from bench to bedside with impressive speed. Learn more in our 2024 Annual Report: 2024.themarkfoundation.org/an-emerging-...
October 9, 2025 at 2:32 PM
The Emerging Leader Award program “lets people follow where the science goes,” says 2019 winner Andrew Lane. That flexibility has allowed him to bring discoveries from bench to bedside with impressive speed. Learn more in our 2024 Annual Report: 2024.themarkfoundation.org/an-emerging-...
A dual breakthrough in #CancerResearch: ASPIRE awardees Bennie Lemmens & Jira Bartek of @ki.se & @scilifelab.se developed tech to visualize DNA replication in stunning detail AND uncovered a key protein that acts as an “on-switch” for the replication process.
themarkfoundation.org/blog/aspire-...
themarkfoundation.org/blog/aspire-...
ASPIRE Awardees Uncover DNA Replication Dynamics with Unprecedented Precision | The Mark Foundation for Cancer Research
DNA replication is a critical biological process that cells use to copy their genome – but when it goes wrong, those failures can have dire consequences. Missteps in the replication process are key…
themarkfoundation.org
October 8, 2025 at 7:33 PM
A dual breakthrough in #CancerResearch: ASPIRE awardees Bennie Lemmens & Jira Bartek of @ki.se & @scilifelab.se developed tech to visualize DNA replication in stunning detail AND uncovered a key protein that acts as an “on-switch” for the replication process.
themarkfoundation.org/blog/aspire-...
themarkfoundation.org/blog/aspire-...
Reposted by The Mark Foundation for Cancer Research
The Mark Foundation for Cancer Research is making a huge impact - in the US and globally 🙌
Very grateful for their support 🙏 - for an #ASPIRE award that funded our microbiome research, and for two #Momentum Fellows in our lab @lbejarano.bsky.social & @ale-matera.bsky.social
@themarkfdn.bsky.social
Very grateful for their support 🙏 - for an #ASPIRE award that funded our microbiome research, and for two #Momentum Fellows in our lab @lbejarano.bsky.social & @ale-matera.bsky.social
@themarkfdn.bsky.social
$34.5 million in awarded grants. 7 new interventional trials. 212 peer-reviewed publications. Read our newly released 2024 Annual Report to catch up on our grantees’ achievements and discover how we’re accelerating progress in the fight against cancer.
2024.themarkfoundation.org
2024.themarkfoundation.org
October 7, 2025 at 8:43 PM
The Mark Foundation for Cancer Research is making a huge impact - in the US and globally 🙌
Very grateful for their support 🙏 - for an #ASPIRE award that funded our microbiome research, and for two #Momentum Fellows in our lab @lbejarano.bsky.social & @ale-matera.bsky.social
@themarkfdn.bsky.social
Very grateful for their support 🙏 - for an #ASPIRE award that funded our microbiome research, and for two #Momentum Fellows in our lab @lbejarano.bsky.social & @ale-matera.bsky.social
@themarkfdn.bsky.social
$34.5 million in awarded grants. 7 new interventional trials. 212 peer-reviewed publications. Read our newly released 2024 Annual Report to catch up on our grantees’ achievements and discover how we’re accelerating progress in the fight against cancer.
2024.themarkfoundation.org
2024.themarkfoundation.org
October 7, 2025 at 7:52 PM
$34.5 million in awarded grants. 7 new interventional trials. 212 peer-reviewed publications. Read our newly released 2024 Annual Report to catch up on our grantees’ achievements and discover how we’re accelerating progress in the fight against cancer.
2024.themarkfoundation.org
2024.themarkfoundation.org
New in @nature.com: past ASPIRE Awardee Trudy Oliver identifies the likely origin of some SCLC tumors. This breakthrough discovery for an aggressive, hard-to-treat disease could enable therapies that target lineage plasticity—a major challenge in cancer.
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Basal cell of origin resolves neuroendocrine–tuft lineage plasticity in cancer - Nature
Basal cells, rather than neuroendocrine cells, have been identified as the probable origin of small cell lung cancer and other neuroendocrine–tuft cancers, explaining neuroendocrine–tuft heterogeneity and offering new perspectives for targeting lineage plasticity.
www.nature.com
October 5, 2025 at 3:38 PM
New in @nature.com: past ASPIRE Awardee Trudy Oliver identifies the likely origin of some SCLC tumors. This breakthrough discovery for an aggressive, hard-to-treat disease could enable therapies that target lineage plasticity—a major challenge in cancer.
www.nature.com/articles/s41...
www.nature.com/articles/s41...
📣Introducing the Samuel Waxman Institute for Aging & Cancer! 📣
As today's NYTimes DealBook reports, the Samuel Waxman Cancer Research Foundation is joining us to launch a world-first institute focused on how the biology of aging drives cancer risk at all life stages.
www.nytimes.com/2025/09/09/b...
As today's NYTimes DealBook reports, the Samuel Waxman Cancer Research Foundation is joining us to launch a world-first institute focused on how the biology of aging drives cancer risk at all life stages.
www.nytimes.com/2025/09/09/b...
September 9, 2025 at 7:02 PM
📣Introducing the Samuel Waxman Institute for Aging & Cancer! 📣
As today's NYTimes DealBook reports, the Samuel Waxman Cancer Research Foundation is joining us to launch a world-first institute focused on how the biology of aging drives cancer risk at all life stages.
www.nytimes.com/2025/09/09/b...
As today's NYTimes DealBook reports, the Samuel Waxman Cancer Research Foundation is joining us to launch a world-first institute focused on how the biology of aging drives cancer risk at all life stages.
www.nytimes.com/2025/09/09/b...